For decades, scientists studying the immune system have faced a frustrating roadblock: a rare but critical type of cell resisted close examination in the laboratory, keeping its secrets locked away. Now, researchers at the University Hospital Bonn have broken through that barrier—and their discovery could reshape how we understand everything from vaccines to autoimmune disease.
Dr. Luisa Bach and her colleagues have developed a new method for growing follicular regulatory T cells—known as Tfr cells—directly from precursor cells in the lab. The technique, published in the journal Cellular & Molecular Immunology, allows researchers to watch these cells develop and study their behavior in unprecedented detail.
Tfr cells act as nature's quality-control inspectors for the immune system. Nestled in the germinal centers of lymph nodes, tonsils, and the spleen, they keep antibody responses from spiraling out of control—ensuring the body makes enough defenders to fight infection without attacking its own tissues. An imbalance between these regulatory cells and their activating counterparts has been linked to autoimmune conditions and inappropriate immune reactions.
"Tfr cells have been difficult to study until now," said Dr. Bach. "With our model, we can now specifically track their development in the laboratory and investigate the molecular mechanisms that control their properties and functions."
The team discovered that a single signaling molecule, TGF-β, holds remarkable power over Tfr cell development—it's both necessary and sufficient to trigger the characteristic program that transforms ordinary immune cells into these specialized regulators. Counterbalancing this is another signal, IL-2, which pushes development in the opposite direction. Only the precise interplay between these two forces produces functional Tfr cells.
They also identified the transcription factor c-Maf as a master regulator of the process: without it, cells fail to develop the traits that make Tfr cells effective controllers.
Perhaps most significantly, the lab-grown Tfr cells behaved just like their natural counterparts. In cell culture experiments, they suppressed the activation of B cells and limited the formation of certain antibody classes—demonstrating that the simplified laboratory model faithfully recreates real immune dynamics.
Dirk Baumjohann, corresponding author and researcher in the Department of Hematology, Oncology, Immuno-Oncology, and Rheumatology at UKB, said the implications extend far beyond basic science. "Tfr cells are among the most important regulators of the antibody response. The fact that their characteristic properties can now be specifically investigated in cell cultures opens up new possibilities for researching their biological function," he explained. "This allows us to better understand how antibody responses are regulated and how misdirected immune reactions arise."
The advance gives immunologists a powerful new tool—one that could eventually inform treatments for autoimmune disorders and improve vaccine design by helping researchers understand exactly what "good" antibody responses look like.